CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following investor conferences:
Leerink Global Healthcare Conference
Thursday, February 27, 2020 at 9:30 a.m. ET
Location: New YorkCowen and Company Annual Health Care Conference
Monday, March 2, 2020 at 3:30 p.m. ET
Location: Boston, MAA live audio webcast of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and has completed extensive pre-clinical research for FTX-6058 for the treatment of sickle cell disease and beta-thalassemia.Please visit www.fulcrumtx.com.Contact:
Christi Waarich
Director, Investor Relations
and Corporate Communications
617-651-8664
[email protected]
Bay Street News
